In vitro evaluation of Haemonetics MCS+ apheresis platelet concentrates treated with photochemical pathogen inactivation following plasma volume reduction using the INTERCEPT Preparation Set

Vox Sang. 2006 Feb;90(2):128-30. doi: 10.1111/j.1423-0410.2005.00723.x.

Abstract

Pathogen inactivation using the INTERCEPT Blood System requires platelet resuspension in InterSol and reduced plasma. Platelets in plasma collected on the Haemonetics MCS+ were processed on the INTERCEPT Preparation Set for plasma volume reduction and addition of InterSol. The use of the Preparation Set resulted in a mean platelet loss of 5.6 +/- 3.4%. Subsequent photochemical treatment (PCT) with amotosalen and ultraviolet A light, and 7 days of storage, resulted in acceptable changes for platelet swirling, lactate, lactate dehydrogenase (LDH), platelet factor-4 (PF4), p-selectin, glycoprotein V (GpV), pO2, pCO2, tumour necrosis factor-alpha (TNF-alpha) and interleukin-8 (IL-8). All platelet units processed with the Preparation Set and PCT met European requirements for leucoreduction and pH values.

Publication types

  • Evaluation Study

MeSH terms

  • Blood Platelets / drug effects
  • Blood Platelets / physiology
  • Blood Platelets / radiation effects
  • Blood-Borne Pathogens / radiation effects
  • Furocoumarins
  • Humans
  • In Vitro Techniques
  • Photochemistry
  • Photosensitizing Agents
  • Plasma Volume
  • Plateletpheresis / instrumentation*
  • Plateletpheresis / methods
  • Solutions
  • Ultraviolet Rays

Substances

  • Furocoumarins
  • Photosensitizing Agents
  • Solutions
  • amotosalen